Abstract: Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: A transdermal formulation which can be applied to the skin, body, face using a combination of glutathione, in the presence of a wide range of active components while increasing permeation of active antioxidant agents. A therapeutically effective amount creates in the patient (i) regulation of sleep, (ii) increased energy during awake periods, (iii) improved concentration during awake periods, (iv) reduction of facial wrinkles, and (v) reduction of joint and muscular pain with increases by at least 10 percent of the ability of skin to retain moisture and totally absorb the glutathione without requiring injection or oral supplementation of the glutathione.

Abstract: Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

Abstract: The present invention disclosed herein relates to synergistic bioactive compositions for treating neurological disorders. Particularly, the invention relates to anti-ischemic nutritional compositions. More particular, the invention relates to synergistic, efficient, nutritional compositions for treating cerebral ischemia comprising therapeutically active exogenous combination of a decarboxylated L-arginine called agmatine (AGM) and a bio-optimized palmitoylethanolamide (Bio-PEA) and salts thereof, wherein the decarboxylated L-arginine salt i.e., agmatine sulfate and bio-optimized palmitoylethanolamide (PEA) are present in a weight ratio of 1:0.1 to 1:5 along with pharmaceutically acceptable excipients.

Abstract: The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of dermatological disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; atopic dermatitis; contact dermatitis; cholestatic itch; psoriasis; sebhorrheic dermatitis; milaria rubra; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates skin discomfort. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy of dermatological disorders.

Abstract: A method for producing a flowable active material-encapsulated core-shell microcapsule composition by mechanically removing solvent from a microcapsule suspension to produce a wet cake, and subsequently charging the wet cake with a dry flow aid, is provided.

Abstract: A modified nano-silica gel for improving symptoms caused by bacteria and viruses and a preparation method and an application thereof. The patented nano-silica gel is modified by a modified compound to obtain a modified nano-silica gel to effectively reduce an amount of toxins excreted by sows, thereby providing piglets with a safe environment that is more suitable for survival. The modified nano-silica gel of the invention comprises: a nano-silica gel with a content of 13.0-92.3 wt %; a modified compound with a content of 0.15-3.50 wt %, the modified compound is an organic compound, a weight ratio of the nano-silica gel to the modified compound is 620:1 to 3.5:1; and water with a formula of H2O and a content of 7.5-86.8 wt %; the nano-silica gel, the modified compound and the water are stirred and mixed at a temperature of 40-80° C. to prepare the modified nano-silica gel.

Abstract: The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (III) as defined herein for treatment of a nematode infection or a disease, disorder or condition arising from a nematode infection.

Abstract: The invention relates to high polyol compositions comprising foaming, preferably mild surfactants. While xanthan gum is normally incompatible with such composition, applicants have surprisingly found compositions (having specified particles size) and process for making such compositions such that xanthan gum can now be used as structurant.

Abstract: Provided are preparation and use of novel compounds available as main ingredients of a composition for promoting hair growth, wherein the novel compounds are 9-deoxo-31-O-demethyl-prolyl-FK506, 9-deoxo-36,37-dihydro-FK506, 31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-31-O-demethyl-36,37-dihydro-FK506, 9-deoxo-FK520, 31-O-demethyl-FK520, 9-deoxo-31-O-demethyl-FK520, 9-deoxo-FK523, and 9-deoxo-31-O-demethyl-FK523.

Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.

Abstract: Provided herein are dry powder formulations comprising at least one active pharmaceutical ingredient suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including respiratory conditions, hemodynamic collapse, seizures, migraines, and other conditions.

Abstract: A method for producing mesoporous magnesium hydroxide nanoplates involving solvothermal treatment of a solution of a magnesium salt, a base, a glycol, and water is disclosed. The method does not use a surfactant or template in the solvothermal treatment. The method yields mesoporous nanoparticles of magnesium hydroxide having a plate-like morphology with a diameter of 20 nm to 100 nm, a mean pore diameter of 2 to 10 nm, a surface area of 50 to 70 m2/g, and a type-III nitrogen adsorption-desorption BET isotherm with a H3 hysteresis loop. An antibacterial composition containing the mesoporous magnesium hydroxide nanoplates is also disclosed. A method for reducing nitroaromatic compounds with a reducing agent and the mesoporous magnesium hydroxide nanoplates as a catalyst is also disclosed.

Abstract: Herein described is a modified release coated capsule and a process to obtain that capsule.

Abstract: A compound 2,4-dichloro-N-[(3-chlorophenyl)carbamothioyl]benzamide, its synthesis, and its use as an insecticidal agent.

Abstract: This disclosure describes a composition including the ginsenoside 20(S)-Rg3 (also referred to herein as Rg3) and methods of using such a composition. In some embodiments, the composition may be used to treat or prevent an alpha herpesvirus including, for example, herpes simplex virus (HSV)-1 and HSV-2. In some embodiments, the composition is substantially free of other ginsenosides.

Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.

Abstract: The invention relates to lyophilized products and reconstituted emulsions for parenteral application, which comprise all the 13 essential vitamins (A, D, E, K1, C, B1, B2, B3, B5, B6, B7, B9, and B12) in a single container, as well as to methods for preparing them.

Abstract: To provide a method for evaluating or selecting an agent for reducing sensory irritation, which reduces sensory irritation caused by parabens, and an agent for reducing sensory irritation, which reduces sensory irritation caused by parabens. A method for evaluating or selecting an agent for reducing sensory irritation caused by parabens, comprising the following steps (1) to (3): (1) a step of contacting cells capable of expressing CES1 with a test substance; (2) a step of measuring expression of CES1 in the cells; (3) a step of evaluating a test substance which promotes expression of CES1 as an agent for reducing sensory irritation caused by parabens based on the results measured in (2).